Search clinical trials for: BI 1744 CL solution for inhalation

Total 80 results

Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Erik Allen Jensen
University of Florida

Active, not recruiting

Inhaled Tobramycin in BPD

Bronchopulmonary Dysplasia

United States
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE)

Acute Viral Bronchiolitis

France
Children's Hospital of Philadelphia

Completed

Hypertonic Saline for Acute Bronchiolitis

Saline Solution, Hypertonic | Bronchiolitis, Viral

United States
Apeptico Forschung und Entwicklung GmbH

Recruiting

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

ARDS

Austria, Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers

Healthy
Merck Sharp & Dohme LLC

Completed

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Lung Cancer
Boehringer Ingelheim

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Netherton Syndrome

Belgium, United Kingdom, Australia, Germany, China, Malaysia, Japan, France, United States, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
Merck Sharp & Dohme LLC

Terminated

Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)

Interstitial Lung Disease
Theravance Biopharma
GlaxoSmithKline; Hammersmith Medicines Research

Completed

A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Healthy
Novartis Pharmaceuticals

Completed

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis (EAGER)

Cystic Fibrosis

United States, Germany, United Kingdom, Colombia, Spain, France, Netherlands, Israel, Canada, Italy, Chile, Australia, Hungary, Mexico
Novartis Pharmaceuticals

Completed

Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

Cystic Fibrosis
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Healthy

Germany
Novartis

Completed

Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis (ELITE)

Cystic Fibrosis
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
AbbVie

Completed

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Puerto Rico
AstraZeneca

Completed

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

Cystic Fibrosis

United States
Boehringer Ingelheim

Completed

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Healthy
Gilead Sciences

Completed

Aztreonam Lysine for Pseudomonas Infection Eradication Study (ALPINE)

Cystic Fibrosis

United States, France, Spain, Germany, Austria, Belgium, Italy, Netherlands, Poland
Bonnie Ramsey
National Heart, Lung, and Blood Institute (NHLBI)

Completed

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis (OPTIMIZE)

Cystic Fibrosis

United States
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Boehringer Ingelheim

Completed

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Pain, Postoperative

Italy
AstraZeneca
Quotient Sciences

Active, not recruiting

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Asthma

United Kingdom
BDD Pharma Ltd
AlgiPharma AS

Completed

A Study to Investigate Lung Deposition of Radiolabelled OligoG

Cystic Fibrosis

United Kingdom
Insmed Incorporated

Completed

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Pseudomonas Aeruginosa Infection

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Denmark, Greece, Canada, Netherlands, Hungary, Italy, Ireland, Sweden, Slovakia, Austria, Serbia
AstraZeneca

Completed

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Healthy
BioInvent International AB
Merck Sharp & Dohme LLC

Recruiting

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Advanced Malignancies

United Kingdom, Denmark, Hungary, Russian Federation

3

Subscribe